bosentan anhydrous has been researched along with Angiospasm, Intracranial in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Algra, A; Rinkel, GJ; Vergouwen, MD | 1 |
| Bodock, MJ; Buonanno, FS; Carter, BS; Koroshetz, WJ; Nogueira, RG; Ogilvy, CS; Pryor, JC; Topcuoglu, MA | 1 |
| Clozel, M | 1 |
2 review(s) available for bosentan anhydrous and Angiospasm, Intracranial
| Article | Year |
|---|---|
Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.
Topics: Bosentan; Contraindications; Dioxanes; Endothelin Receptor Antagonists; Humans; Incidence; Peptides, Cyclic; Pyridines; Pyrimidines; Receptors, Endothelin; Subarachnoid Hemorrhage; Sulfonamides; Tetrazoles; Treatment Outcome; Vasospasm, Intracranial | 2012 |
Endothelin receptor antagonists: current status and perspectives.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension; Subarachnoid Hemorrhage; Sulfonamides; Vasospasm, Intracranial | 2000 |
1 trial(s) available for bosentan anhydrous and Angiospasm, Intracranial
| Article | Year |
|---|---|
High-dose bosentan in the prevention and treatment of subarachnoid hemorrhage-induced cerebral vasospasm: an open-label feasibility study.
Topics: Adult; Antihypertensive Agents; Bosentan; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Male; Middle Aged; Pilot Projects; Subarachnoid Hemorrhage; Sulfonamides; Vasospasm, Intracranial | 2007 |